L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial–mesenchymal transition
de Bruyn, M
Nijman, Hans W.
de Bock, GH
MetadataShow full item record
Uterine carcinosarcoma (UCS) has been proposed as a model for epithelial–mesenchymal transition (EMT), a process characterized by a functional change facilitating migration and metastasis in many types of cancer. L1CAMis an adhesion molecule that has been involved in EMT as a marker for mesenchymal phenotype.We examined expression of L1CAM in UCS in a cohort of 90 cases from four different centers. Slides were immunohistochemically stained for L1CAMand scored in four categories (0%, < 10%, 10–50%, and > 50%). A score of more than 10% was considered positive for L1CAM. The median age at presentation was 68.6 years, and half of the patients (53.3%) presented with FIGO stage 1 disease. Membranous L1CAM expression was positive in the epithelial component in 65.4% of cases. Remarkably, expression was negative in the mesenchymal component. In cases where both components were intermingled, expression limited to the epithelial component was confirmed by a double stain for L1CAMand keratin. Expression of L1CAMdid not relate to overall or disease-free survival. Our findings suggest L1CAMis either not a marker for the mesenchymal phenotype in EMT, or UCS is not a good model for EMT.
Is part ofVirchows Archiv, 2018
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by (c) MAC Versluis et al., 2018
Showing items related by title, author, creator and subject.
Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples Martínez García, Elena; Lesur, Antoine; Devis, Laura; Rosa Campos, Alexandre; Cabrera, Silvia; Oostrum, Jan van; Matias-Guiu, Xavier; Gil-Moreno, Antonio; Reventós, Jaume; Colás, Eva; Domon, Bruno (Impact Journals, 2016)About 30% of endometrial cancer (EC) patients are diagnosed at an advanced stage of the disease, which is associated with a drastic decrease in the 5-year survival rate. The identification of biomarkers in uterine aspirate ...
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer Alonso-Alconada, Lorena; Muinelo-Romay, Laura; Madissoo, Kadri; Díaz-López, Antonio; Krakstad, Camilla; Trovik, Jone; Wik, Elisabeth; Hapangama, Dharani; Coenegrachts, Lieve; Cano, Amparo; Gil-Moreno, Antonio; Chiva, Luís; Cueva, Juan; Vieito, María; Ortega Izquierdo, Maria Eugenia; Mariscal, Javier; Colás, Eva; Castellví, Josep; Cusido, Maite; Dolcet Roca, Xavier; Nijman, Hans W.; Bosse, Tjalling; Green, John A.; Romano, Andrea; Reventós, Jaume; López-López, Rafael; Salvesen, Helga B.; Amant, Frederic; Matias-Guiu, Xavier; Moreno-Bueno, Gema; Abal, Miguel (Biomed Central, 2014)Background: About 20% of patients diagnosed with endometrial cancer (EC) are considered high-risk with unfavorable prognosis. In the framework of the European Network for Individualized Treatment in EC (ENITEC), we ...
Megino-Luque, Cristina; Moiola, Cristian P.; Molins-Escuder, Clara; López-Gil, Carlos; Gil-Moreno, Antonio; Matias-Guiu, Xavier; Colás, Eva; Eritja Sánchez, Núria (MDPI, 2020-09-24)Endometrial cancer (EC) is the sixth most common cancer in women. A continued number of low-risk EC patients at diagnosis, as well as patients diagnosed with advanced-stage disease, will experience an aggressive disease. ...